Invex Therapeutics Ltd.
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
A Trial to Determine the Efficacy and Safety of Presendin in IIH
Phase 3
Terminated
- Conditions
- Idiopathic Intracranial Hypertension
- Interventions
- Drug: PlaceboDrug: Presendin
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Invex Therapeutics Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05347147
- Locations
- 🇺🇸
New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States
🇺🇸University of Miami Leonard M. Miller School of Medicine (UMMSM) - Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸The University of Texas Southwestern Medical Center, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath